Using biomaterials to control immune responses for treating autoimmune diseases
Local immunometabolism modulating biomaterials for immunosuppressive applications
This study is exploring how special materials can help control the immune system by using a substance called alpha-ketoglutarate, aiming to create new treatments for autoimmune diseases and inflammation that are safer and more targeted.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11074629 on NIH RePORTER |
What this research studies
This research investigates how biomaterials can be used to modulate immune responses, particularly focusing on a metabolite called alpha-ketoglutarate. The approach involves creating drug delivery systems that can locally deliver glycolysis inhibitors and antigens to dendritic cells, which play a crucial role in the immune system. By suppressing the activation of these cells while maintaining their ability to present antigens, the goal is to achieve targeted immunosuppression without the toxic effects associated with systemic treatments. This could lead to new therapies for autoimmune conditions and inflammation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from autoimmune diseases or conditions characterized by excessive inflammation.
Not a fit: Patients with non-autoimmune conditions or those not experiencing immune system dysregulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for patients with autoimmune diseases by reducing harmful immune responses.
How similar studies have performed: Other research has shown promise in using biomaterials for immune modulation, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Acharya, Abhinav — Case Western Reserve University
- Study coordinator: Acharya, Abhinav
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.